Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Verastem, Inc. (VSTM : NSDQ)

• Company Description    Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. Number of Employees: 48

• Price / Volume Information    Yesterday's Closing Price: $1.25 Daily Weekly Monthly 20 Day Moving Average: 1,577,543 shares Shares Outstanding: 186.36 (millions) Market Capitalization: $232.95 (millions) Beta: 0.88 52 Week High: $4.94 52 Week Low: $1.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.87% -12.26% 12 Week 1.63% 14.22% Year To Date -39.02% -25.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 117 KENDRICK STREET SUITE 500 - NEEDHAM,MA 02494 USA ph: 781-292-4200 fax: - bsullivan@verastem.com http://www.verastem.com

• General Corporate Information    Officers Brian Stuglik - Chief Executive Officer and Director Daniel Paterson - President and Chief Operating Officer Robert Gagnon - Chief Business and Financial Officer Timothy Barberich - Director Paul Bunn - Director Peer Information Verastem, Inc. (CORR.) Verastem, Inc. (RSPI) Verastem, Inc. (CGXP) Verastem, Inc. (BGEN) Verastem, Inc. (GTBP) Verastem, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92337C104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/01/22 Share - Related Items Shares Outstanding: 186.36 Most Recent Split Date: (:1) Beta: 0.88 Market Capitalization: $232.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.39 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/01/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.20 Price/Cash Flow: - Price / Sales: 63.94 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 158.05% vs. Previous Quarter: 376.33% ROE 03/31/22 - -84.99 12/31/21 - -76.14 09/30/21 - -74.26 ROA 03/31/22 - -63.51 12/31/21 - -59.17 09/30/21 - -56.61 Current Ratio 03/31/22 - 6.72 12/31/21 - 5.69 09/30/21 - 8.03 Quick Ratio 03/31/22 - 6.72 12/31/21 - 5.69 09/30/21 - 8.03 Operating Margin 03/31/22 - -2,007.44 12/31/21 - -3,468.09 09/30/21 - -3,703.23 Net Margin 03/31/22 - -2,007.44 12/31/21 - -3,468.09 09/30/21 - -3,703.23 Pre-Tax Margin 03/31/22 - -2,007.44 12/31/21 - -3,468.09 09/30/21 - -3,693.59 Book Value 03/31/22 - 0.39 12/31/21 - 0.48 09/30/21 - 0.53 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.34 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 25.12 12/31/21 - 0.28 09/30/21 - 0.25

Powered by Zacks Investment Research ©